Pacira BioSciences Demonstrates Sustained Momentum with Strategic Growth Initiatives

Pacira US6951271005

Pacira BioSciences has reported a robust performance for the 2025 fiscal year, marked by revenue growth and continued strategic expansion. The company's trajectory is primarily fueled by its flagship product, while a significant share repurchase program underscores management's confidence in its future. The key question for investors is whether this positive momentum can be sustained throughout the current year.

The company's total revenue for 2025 reached $726.4 million, an increase from $701.0 million in the prior year. A breakdown of the figures reveals the drivers behind this growth:

• Total Revenue 2025: $726.4 million (Previous Year: $701.0 million)
• EXPAREL Revenue 2025: $575.1 million (Previous Year: $549.0 million)
• Q4 Share Repurchases: 2.0 million common shares
• Remaining Buyback Authorization: $150 million (available through end of 2026)

EXPAREL Drives Revenue, Offsetting Minor Softness Elsewhere

The non-opioid pain management drug EXPAREL remains the cornerstone of Pacira's success. For the full year, it contributed $575.1 million to the top line. In the fourth quarter alone, EXPAREL revenues advanced to $155.8 million, up from $147.7 million in the same period a year earlier.

This strong performance more than compensated for a slight decline in revenue from ZILRETTA, which dipped to $116.6 million for the year from $118.1 million. Meanwhile, the iovera cryoanalgesia system showed positive development, with annual sales rising to $24.2 million from $22.8 million. The company's overall revenue trend remains firmly upward, a position further strengthened by the cessation of EXPAREL royalty payments as of last April, which has enhanced financial flexibility.

Strategic Moves Position Company for Future Growth

Management is actively deploying capital to support shareholder value. During the final quarter, Pacira bought back 2.0 million of its own shares. This is part of a broader $300 million repurchase program authorized in April 2025, of which $150 million remains available for use.

Concurrently, the company is accelerating its international footprint. A recently announced agreement with LG Chem, finalized in mid-January, will expand the distribution of EXPAREL into select markets across the Asia-Pacific region. Pacira is also strengthening its leadership, having appointed Samit Hirawat to its Board of Directors just over a week ago.

Forward-Looking Catalysts and Expectations

Investors can anticipate the release of Pacira's complete, audited financial statements and a detailed 2026 forecast later in the first quarter. Another significant milestone on the horizon is the expected release of initial data from Part A of the Phase 2 study for PCRX-201. This gene therapy candidate for knee osteoarthritis is slated to report results before the end of 2026. This underscores that alongside the commercial execution for EXPAREL, the clinical development pipeline remains a critical factor for the company's long-term valuation.